Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
Status:
Recruiting
Trial end date:
2023-08-15
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well gadolinium and ferumoxytol magnetic resonance imaging
(MRI) work in diagnosing patients with abnormalities in the central nervous system.
Diagnostic procedures, such as gadolinium and ferumoxytol MRI, may help find and diagnose
abnormalities in the central nervous system.
Phase:
Phase 2
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
Celgene Corporation National Cancer Institute (NCI) Oregon Health and Science University